USA flag logo/image

An Official Website of the United States Government

Biologic approach to targeting a nicotinic receptor accessory molecule for…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
R43MH094004
Solicitation Year:
2011
Solicitation Topic Code:
NIMH
Solicitation Number:
PA08-142
Small Business Information
OPHIDION, INC.
2265 E. Foothill Blvd Pasadena, CA 91107-0000
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: Biologic approach to targeting a nicotinic receptor accessory molecule for cognit
Agency: HHS
Contract: 1R43MH094004-01
Award Amount: $656,365.00
 

Abstract:

DESCRIPTION (provided by applicant): The proposed project details a biologic strategy for the therapeutic targeting of nicotinic receptors of the cholinergic system for the treatment of mental and neurological disorders. The cholinergic system is an important modulatory neurotransmitter system, regulating reward, learning and memory, attention, and cognitive functions. The nicotinic acetylcholine receptor, a major receptor of the cholinergic system, is regulated by modulatory accessory proteins which bind to nicotinic acetylcholine receptors and dampen their function. Biological proof of concept studies in our mouse models indicate that regulating cholinergic tone has a beneficial enhancement of complex circuits in the brain, leading to enhanced learningand memory function. In order to develop a therapeutic intervention recapitulating this cognitive enhancement, we propose to develop a biological therapeutic to enhance cholinergic tone in the brain through accessory molecules to nicotinic receptors. Because the blood brain barrier is the most challenging problem facing the delivery of the macromolecules to neurons in the brain, we propose several strategies for optimizing delivery based on peptides with demonstrated ability to deliver therapeutic candidates past the blood- brain barrier. We will couple the most efficient translocators. We will test the functional inhibition by therapeutic candidates on our established nicotinic receptor cell lines and assays. In addition, we will label potential carrier molecules to assess their blood-brain penetrability, and finally test the efficacy of candidates in vivo in our mouse models. If successful the outcome will lead to the development of a therapeutic candidate to treat cognitive and memory impairments associated with mental and neurological disorders, such as schizophrenia, Alzheimer's and Parkinson's disease, and depression. PUBLIC HEALTH RELEVANCE: This project involves the development of therapeutic interventions to treat the cognitive dysfunctionassociated with mental and neurological disorders, such as schizophrenia, Alzheimer's disease, Parkinson's disease, depression, and ADHD.

Principal Investigator:

Andreas Walz
646-326-9717
andreas.walz@ophidionbio.com

Business Contact:

Andreas Walx
646-327-9717
andreas.walz@ophidionbio.com
Small Business Information at Submission:

OPHIDION, INC.
2265 E. Foothill Blvd Pasadena, CA 91107-0000

EIN/Tax ID: 126188525
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No